Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH2853 in relapsed/refractory NHL and advanced solid tumors
NCT04390737Phase 2Recruiting
- Sponsor
- Haihe
- Start
- Sep 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of HH2853 in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), non-Hodgkin lymphoma (NHL), epithelioid sarcoma (ES), sponsored by Haihe. Started Sep 2020; status: recruiting.
02
Drugs
HH2853
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)non-Hodgkin lymphoma (NHL)epithelioid sarcoma (ES)
Beyond the preview
Go deeper on NCT04390737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390737.